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Markers of Basement Membrane Remodeling Are Associated With
Higher Mortality in Patients With Known Atherosclerosis
Signe Holm Nielsen, MSc, PhD;* Christoffer Tengryd, MD;* Andreas Edsfeldt, MD, PhD; Susanne Brix, MSc, PhD; Federica Genovese, MSc,
PhD; Eva Bengtsson, MSc, PhD; Morten Karsdal, MSc, PhD; Diana J. Leeming, MSc, PhD; Jan Nilsson, MD, PhD; Isabel Goncalves, MD, PhD
Background-—Patients with atherosclerosis have a high risk of cardiovascular events and death. Atherosclerosis is characterized
by accumulation of lipids, cells and extracellular matrix proteins in the intima. We hypothesized that dysregulated remodeling of the
basement membrane proteins may be associated with clinical outcomes in patients with atherosclerosis.
Methods and Results-—Neoepitope fragments of collagen type IV (C4M) and laminin (LG1M) were assessed by ELISAs in serum
from 787 endarterectomy patients. Matrix metalloproteinases were measured using proximity extension assay and correlated to
C4M and LG1M levels using Spearman correlations. A total of 473 patients were followed up for 6 years using national registers,
medical charts, and telephone interviews. The incidence of cardiovascular events, cardiovascular mortality, and all-cause mortality
were associated to levels of C4M and LG1M using Kaplan–Meier curves and Cox regression analyses. A total of 101 patients had
cardiovascular events, 39 died of cardiovascular mortality, and 64 patients died from all-cause mortality. C4M levels were
increased in patients with symptomatic carotid atherosclerotic disease before surgery (P=0.048). High C4M and LG1M levels were
associated with increased risk of all-cause mortality (P=0.020 and 0.031, respectively) and predicted all-cause death together with
glomerular ﬁltration rate and diabetes mellitus.
Conclusions-—High LG1M and C4M levels were associated with all-cause mortality, together with glomerular ﬁltration rate and
diabetes mellitus. These novel biomarkers need further evaluation but might be tools to identify high-risk patients. ( J Am Heart
Assoc. 2018;7:e009193. DOI: 10.1161/JAHA.118.009193.)
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C ardiovascular disease is, despite advancement in treat-ments, still the major cause of mortality and morbidity
worldwide.1,2 One of the most important underlying causes of
cardiovascular disease is atherosclerosis. Atherosclerosis is a
systemic disease characterized by development of plaques
containing lipids, inﬂammatory cells, apoptotic cells, calcium,
and extracellular matrix proteins in the arterial wall. Thrombus
formation on top of ruptured atherosclerotic plaques is a
major cause of acute cardiovascular events. Plaques that are
prone to rupture, vulnerable plaques, have larger lipid-rich
cores, more inﬂammatory cells, and thinner ﬁbrous caps that
are degraded by proteases.3,4 However, there is accumulating
evidence that lifestyle changes in combination with a more
frequent use of cholesterol-lowering therapies have changed
the characteristics of the disease and that traditional
vulnerable plaques are becoming less common.5–7 Instead,
recent studies reveal that today as much as 30% to 40% of all
cardiovascular events are caused by thrombus formation on
the surface of plaques with an intact and thick ﬁbrous cap.
These events are considered to be caused by endothelial
erosion, but the pathophysiological mechanisms responsible
for development of these remain to be fully understood.8,9
The endothelial cells covering the luminal side of arteries
rest on top of an extracellular matrix structure known as the
From the Nordic Bioscience, Biomarkers and Research, Herlev, Denmark (S.H.N., F.G., M.K., D.J.L.); Disease Systems Immunology, Department of Biotechnology and
Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark (S.H.N., S.B.); Experimental Cardiovascular Research Unit, Department of Clinical Sciences,
Malm€o, Lund University, Malm€o, Sweden (C.T., A.E., E.B., J.N., I.G.); Department of Cardiology, Skane University Hospital, Malm€o, Sweden (A.E., I.G.).
Accompanying Tables S1 through S3 and Figure S1 are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.009193
*Dr Holm Nielsen and Dr Tengryd are co-ﬁrst authors.
This work was presented at the European Society of Cardiology Congress, August 25 to 29, 2018, in Munich, Germany.
Correspondence to: Signe Holm Nielsen, MSc, PhD, Nordic Bioscience, Herlev Hovedgade 205-207, 2730 Herlev, Denmark. E-mail: shn@nordicbio.com
Received June 15, 2018; accepted August 27, 2018.
ª 2018 The Authors and Nordic Bioscience A/S. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the
terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.118.009193 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on December 4, 2018
basement membrane. The vascular basement membrane is a
thin, sheet-like structure mainly composed of laminin and
collagen type IV.10,11 Similar basement membranes also
surround smooth muscle cells in the media of the artery wall.
In a healthy artery, matrix metalloproteinases (MMPs) are able
to degrade collagen type IV and laminin and induce de novo
synthesis of new proteins and maintain tissue homeostasis of
the basement membrane.12 In atherosclerosis, MMP activity
is increased, causing accelerated basement membrane
degradation.12,13 Circulating fragments of basement mem-
brane proteins in serum could thus reﬂect the accelerated
remodeling of the arterial basement membrane and function
as a marker of degraded basement membrane, vascular tissue
remodeling, and possibly also endothelial erosions.
Here, we evaluated newly developed immunoassays for the
detection of the neoepitope fragments C4M (MMP-2, -9 and
-12-mediated degradation of collagen type IV) and LG1M
(MMP-9-mediated degradation of the laminin-y1 chain) in
serum of patients with atherosclerosis. Our aim was to study
whether the circulating levels of these markers were associ-
ated with (1) cardiovascular events, (2) cardiovascular death,
and (3) all-cause mortality in patients with advanced
atherosclerosis.
Materials and Methods
Transparency and Openness
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. The human
material is from a biobank cohort, and the samples are limited
and cannot leave the Experimental Cardiovascular Research
Unit at Lund University, Malm€o, Sweden, because of regula-
tory and ethical permission issues.
Study Population
A total of 787 human serum samples were collected on
the day before carotid endarterectomy. The indications for
surgery were plaques associated with ipsilateral symptoms
(transient ischemic attack, stroke, or amaurosis fugax) and
stenosis measured by duplex >70% (n=610) or plaques not
associated with symptoms and stenosis >80% (n=177). All
patients were preoperatively examined by a neurologist.
Clinical data regarding cardiovascular risk factors, namely,
hypertension (systolic blood pressure >140 mm Hg), dia-
betes mellitus, smoking, levels of fasting lipoproteins (total
cholesterol, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, and triglycerides), as well as the
use of statins and antihypertensive drugs, were registered
the day before surgery. Serum samples were processed
immediately after collection according to predeﬁned stan-
dard operating procedures and stored at 80°C until
analysis. Informed consent was obtained from the study
participants, and the study was approved by the local
ethical committee.
Follow-Up
The primary outcomes comprised: (1) cardiovascular events,
(2) cardiovascular mortality, (3) all-cause mortality, all within
6 years. The cardiovascular events studied longitudinally
included myocardial infarction, transient ischemic attacks,
amaurosis fugax, and vascular interventions not planned at
the time of the operation such as carotid endarterectomy,
carotid artery stenting, coronary artery bypass grafting, or
percutaneous coronary artery intervention, and all deaths with
an underlying cardiovascular cause of death. Cardiovascular
events were located by analyzing the Swedish National
Patient Register for all hospital discharge codes for all the
patients included in the study. Patients were identiﬁed
through their personal identiﬁcation number. The Swedish
National patient register has a high coverage with 99% of all
somatic (including surgery) and psychiatric hospital dis-
charges registered.14 The following International Classiﬁcation
of Diseases, Tenth Revision (ICD-10) codes were used to
identify cardiovascular events: G45.9, G45.3, G46, I63.1 to 5,
I63.8 to 9, I64.5, I21 to 22, I24.8 to 9, I25.1 to 2, I25.5 to 6,
and I25.8.
All events were veriﬁed by patient medical charts and by
telephone interviews. Events occurring within 72 hours after
carotid endarterectomy were considered procedure related
Clinical Perspective
What Is New?
• In this study, we found 2 serologic biomarkers measuring
basement membrane remodeling, as possible tools to
identify patients with a high risk of a second cardiovascular
event and/or death.
• These biomarkers measure matrix metalloproteinase–gen-
erated epitopes of collagen type IV (C4M) and laminin
(LG1M), which are structural components of the basement
membrane.
• This is, to our knowledge, the ﬁrst study describing neoepi-
tope-speciﬁc basement membrane biomarkers as prognostic
biomarkers in patients with known atherosclerosis.
What Are the Clinical Implications?
• These markers may provide valuable information detecting
subjects in need of intensiﬁed strategies for secondary
prevention.
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and were not included in the analysis. For patients having
multiple events, only the ﬁrst one was taken into account in
the survival analysis.
All deaths were extracted from the Swedish cause-of-death
register.15 In this study, the following underlying cause of
death ICD-10 codes were used to deﬁne cardiovascular
mortality: I21.9, I25.1, I25.8 to 9, I48, I50.9, I60.9, I61.9,
I63.2, I64, I69.4, I71.0, I73.9, I74.9, and I99.
ELISA Measurement of C4M and LG1M
The 2 markers measured in this study included markers of
collagen type IV and laminin degradation, which were
measured by competitive ELISAs developed by Nordic
Bioscience (Herlev, Denmark).16 Brieﬂy, a 96-well ELISA plate
purchased coated with streptavidin (cat. 11940279, Roche,
Hvidovre, Denmark) was coated with the synthetic peptide
and incubated at 20°C for 30 minutes with constant shaking
at 300 rpm. The plate was then washed 5 times in washing
buffer (20 mmol/L Tris, 50 mmol/L NaCl, pH 7.2). There-
after, 20 lL of the standard peptide or sample diluted
according to the protocol were added, followed by 100 lL of
peroxidase conjugated antihuman monoclonal antibodies. The
plate was incubated for 1 hour at 20°C or for 3 hours at 4°C
with constant shaking at 300 rpm (according to the speciﬁ-
cations for the individual assay). Afterwards, the plate was
washed 5 times in washing buffer, 100 lL 3,30,5,50 tetram-
ethyl-benzidine (Kem-En-Tec, Taastrup, Denmark) was added,
and the plate was incubated for 15 minutes in the dark with
constant shaking at 300 rpm. The reaction was stopped by
the addition of 100 lL stop solution (1% H2SO4), and the
plate was analyzed on an ELISA reader at 450 nm with
650 nm as the reference wavelength. All samples were
measured within the detection range of the assay. Samples
below the lower limit of quantiﬁcation were assigned the value
of LLOQ, while samples above upper limit of quantiﬁcation
were assigned the value of ULOQ.
MMP-1, -3, -7, -10 and 12 Measurement by
Proximity Extension Assay
Circulating levels of plasma levels of MMP-1, -3, -7, -10 and
-12 were assessed in 551 patients using the proximity
extension assay technique using the Proseek Multiplex
CVD96996 reagents kit (Olink Bioscience, Uppsala, Sweden)
at the Clinical Biomarkers Facility, Science for Life Laboratory,
Uppsala, as previously described.17
Statistical Analysis
Baseline characteristics are described as number (frequency)
and percentage for categorical variables, and as median
(interquartile range) for continuous variables, as presented
variables were non-normally distributed. Spearman correla-
tions were used because the levels of C4M and LG1M were
not normally distributed.
Kaplan–Meier survival analyses were performed for C4M
and LG1M, divided according to the median value of each
marker (high versus low) for the 3 primary outcomes.
Signiﬁcant differences between the groups were assessed
by a log-rank test. Cox proportional hazard regression analysis
(hazard ratios [HRs] with 95% conﬁdence interval [CI]) was
used to analyze the time-to-event association between
baseline characteristics and risk of cardiovascular events,
cardiovascular mortality, and all-cause mortality. Multivariate
models were created, correcting for known cardiovascular risk
factors: age, sex, hypertension, diabetes mellitus, current
smoking, total cholesterol, and estimated glomerular ﬁltration
rate (eGFR). These parameters were chosen based on the
Framingham risk score18 and on the fact that patients with
diabetes mellitus have per se a 2- to 4-fold increased risk of
cardiovascular disease.18,19 The proportional hazards assump-
tion was assessed using Cox regression with time-dependent
covariate in SPSS. P<0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using SPSS,
version 24 (IBM Corporation).
Results
Baseline Characteristics of the Study Cohort
The study participants were 63.9% male, median age was
72 years (interquartile range, 66–77) and median body
mass index was 26.4 (interquartile range, 24.0–29.3). The
median degree of stenosis was 90% (interquartile range,
75–95), and 77.5% of the patients had a symptomatic
carotid plaque. Baseline demographics and clinical and
laboratory data for the study cohort divided by the median
of C4M and LG1M are presented in Tables 1 and 2,
respectively.
When dividing the cohort by the median C4M levels,
patients above the median had higher levels of total
cholesterol, low-density lipoprotein, and C-reactive protein
and a lower eGFR and high-density lipoprotein levels. When
dividing the cohort by the median levels of LG1M, patients
above the median levels of LG1M were more commonly
current smokers and had higher levels of C-reactive protein
and lower high-density lipoprotein levels compared with
patients with LG1M below the median.
C4M levels were associated with decreased kidney
function as assessed by eGFR (r=0.230, P=0.001).
Current smokers had a signiﬁcantly higher level of LG1M
at inclusion (8.5 [8.5–14.39] ng/mL versus 9.45 [8.5–
18.05] ng/mL; P=0.009). No signiﬁcant differences in levels
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of C4M and LG1M were found for patients with previous
coronary artery disease, hypertension, or diabetes mellitus
at inclusion.
Follow-Up Outcomes
A total of 101 patients suffered from cardiovascular events
during the 6-year follow-up period. Thirty-nine patients (60.9%
of total deaths) died of cardiovascular causes, and 64 patients
died of all causes during the 6-year follow-up.
C4M and Cardiovascular Events
C4M levels were not signiﬁcantly associated with cardiovas-
cular events even though a trend was seen for high levels of
C4M and an increased risk for cardiovascular events (log-rank
test, P=0.053; Figure 1A). The univariate Cox regression
showed an HR for C4M of 1.51; 95% CI, 0.99–2.29; and
P=0.056. When correcting for known cardiovascular risk
factors (age, sex, hypertension, diabetes mellitus, current
smoking, total cholesterol, and eGFR) with a multivariate Cox
analysis, C4M was not an independent predictor of future
cardiovascular events (HR for C4M, 1.48; 95% CI, 0.95–2.32;
P=0.083; Table 3, Table S1).
C4M and Cardiovascular Mortality
With regard to C4M and cardiovascular mortality, the Kaplan–
Meier curves are shown in Figure S1A. For C4M, statistical
signiﬁcance was not obtained in the log-rank test, the
univariate Cox regression, or the multivariate Cox regression
analysis (HR for C4M, 1.65; 95% CI, 0.77–3.52; P=0.164),
when adjusting for cardiovascular risk factors (age, sex,
hypertension, diabetes mellitus, current smoking, total
cholesterol, and eGFR) (Table 3, Table S1).
C4M and All-Cause Mortality
Patients with high C4M had increased risk of all-cause
mortality (log-rank test, P=0.011; Figure 2A). In the univariate
Cox regression, C4M predicted all-cause mortality (HR, 2.05;
95% CI, 1.16–3.61; P=0.013). In the multivariate Cox
regression analysis, C4M (HR, 2.08; 95% CI, 1.12–3.87;
P=0.02), diabetes mellitus (HR, 1.94; 95% CI, 1.12–3.36;
Table 1. Clinical Characteristics of the Study Cohort Divided by the Median of C4M (Cutoff, 20.5 ng/mL)
Low (n=326) High (n=461) P Value
Age 71 (66–77) 72 (66–78) 0.536
Male sex, n (%) 223 (68.4) 280 (60.7) 0.027*
Degree of stenosis, % 85 (75–95) 90 (75–95) 0.144
BMI 26.4 (24–29.3) 26.4 (24.1–29.3) 0.687
Current smoker, n (%) 93 (28.5) 162 (35.1) 0.051
Hypertension, n (%) 240 (73.6) 355 (77.0) 0.540
Symptomatic plaque, n (%) 244 (74.8) 366 (79.4) 0.132
Fasting plasma levels of lipids
Cholesterol, mmol/L 4.2 (3.5–5.1) 4.4 (3.7–5.4) 0.035*
LDL, mmol/L 2.40 (1.7–3.3) 2.7 (2.0–3.5) 0.004*
HDL, mmol/L 1.2 (0.98–1.52) 1.1 (0.90–1.40) 0.003*
Triglycerides, mmol/L 1.26 (0.9–1.7) 1.3 (1.0–1.8) 0.170
Diabetes mellitus, n (%) 83 (25.5) 115 (24.9) 0.870
Coronary artery disease, n (%) 128 (39.3) 167 (36.2) 0.251
CRP, mmol/L 2.0 (0.6–3.0) 4.0 (2.0–9.4) <0.001*
HbA1c, mmol/mol 44 (38–53.13) 42.34 (38–50.00) 0.274
Medications, n (%)
Statins 304 (83.3) 400 (56.8) 0.004*
Antihypertensive drugs 255 (78.2) 362 (78.5) 0.919
eGFR mL/min per 1.73 m2 67.36 (54.67–83.13) 62.41 (48.59–76.58) 0.009*
Nonnormally distributed data variables are presented as median (interquartile range). Categorical values are presented as numbers and percentages. BMI indicates body mass index; CRP,
C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Signiﬁcant difference between low and high levels of C4M.
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P=0.018) and eGFR (HR, 0.97; 95% CI, 0.96–0.99; P=0.004)
predicted all-cause mortality, whereas the other covariates
were not signiﬁcant in this model (Table 3, Table S1).
C4M and Preoperative Symptoms
Patients who suffered from preoperative cerebrovascular
symptoms had higher levels of C4M compared with asymp-
tomatic patients (20.82 [17.31–26.23] ng/mL versus 19.78
[16.95–24.84] ng/mL; P=0.048; Figure 3A).
Correlations Between C4M and MMP-1, -3, -7, -10
and -12
Because the C4M neoepitope fragments are formed after
MMP cleavage of collagen type IV, we examined whether
circulating levels of MMPs were associated with C4M.
C4M correlated with MMP-1 (r=0.088; P=0.039), MMP-7
(r=0.133; P=0.002), MMP-10 (r=0.118; P=0.006) and MMP-12
(r=0.191; P<0.001), but not with MMP-3 (r=0.049; P=0.338).
LG1M and Cardiovascular Events
With regard to LG1M and its association with cardiovascular
events, statistical signiﬁcance was not obtained in the log-rank
test (Figure 1B), the univariate, or the multivariate Cox
regression analysis adjusting for cardiovascular risk factors
(age, sex, hypertension, diabetes mellitus, current smoking,
total cholesterol, and eGFR (Table 3, Table S2). Only eGFR was
signiﬁcant in themodel with anHR of 0.97; 95%CI, 0.96 to 0.99;
and P=0.028. When analyzing LG1M as a continuous variable
(instead of using the cutoff of median for LG1M high and low) in
a univariate Cox analysis, LG1M predicted cardiovascular
events (HR, 1.01; 95% CI, 1.0–1.03; P=0.033), whereas it did
not remain signiﬁcant in the multivariate analyses (Table S3).
LG1M and Cardiovascular Mortality
Patients with high LG1M levels (above median) had an
increased risk of cardiovascular mortality (log-rank test,
P=0.044; Figure S1B). In a univariate Cox regression analysis,
a trend was observed for LG1M and increased cardiovascular
mortality (HR for LG1M,:1.91; 95% CI, 1.00–3.64; P=0.050).
When performing a multivariate Cox regression analysis
adjusting for the previously described covariates, LG1M did
not predict cardiovascular mortality (Table 3, Table S2). When
analyzing LG1M as a continuous variable (instead of using the
cutoff of median for LG1M high and low) in a univariate Cox
analysis, LG1M predicted cardiovascular mortality (HR, 1.02;
95% CI, 1.01–1.04; P=0.013), whereas it did not remain
signiﬁcant in the multivariate analyses (Table S3).
LG1M and All-Cause Mortality
Kaplan–Meier curves for all-cause mortality of LG1M is shown
in Figure 2B. Patients with high levels of LG1M also had an
increased all-cause mortality (log-rank test, 0.006). The
increased risk for all-cause mortality was also conﬁrmed in
the univariate Cox regression analysis (HR, 2.01; 95% CI, 1.21–
3.34; P=0.007). Adjusting for the covariates described above,
Figure 1. Associations of C4M and LG1M with cardiovascular events. A total of 101 patients suffered from cardiovascular events during the 6-
year follow-up period. A, Kaplan–Meier curves for cardiovascular events were performed for C4M levels above and below the median. There were
no signiﬁcant differences (P=0.053). B, Kaplan–Meier curves for cardiovascular (CV) events were performed for LG1M levels above and below
the median. There were no signiﬁcant differences (P=0.150).
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in a multivariate Cox regression analysis, LG1M, diabetes
mellitus, and eGFR predicted all-cause mortality (Table 3,
Table S2). When analyzing LG1M as a continuous variable
(instead of using the cutoff of median for LG1M high and low)
in a univariate Cox analysis, LG1M predicted all-cause
mortality (HR, 1.03; 95% CI, 1.02–1.05; P<0.001). Additionally,
in the multivariate analyses, it also predicted all-cause
mortality (HR, 1.02; 95% CI, 1.01–1.03; P=0.007) together
with eGFR (HR, 0.97; 95% CI, 0.96–0.99; P=0.004) (Table S3).
LG1M and Preoperative Symptoms
A trend toward increased levels of LG1M was also found in
patients who had preoperative symptoms compared with
those who had not (16.17 [8.5–28–22] ng/mL versus 8.5
[8.5–14–41] ng/mL; P=0.081; Figure 3B).
Correlations Between LG1M and MMP-1, -3, -7,
-10 and -12
LG1M correlated with MMP-7 (r=0.143; P=0.001), MMP-10
(r=0.208; P<0.001), and MMP-12 (r=0.177; P<0.001), but not
with MMP-1 (r=0.031; P=0.46) and MMP-3 (r=0.075,
P=0.137).
Taken together, this implies that there might be an
association between MMP-induced breakdown of the
basement membrane and the levels of circulating neo-
epitopes.
Discussion
In the present study, we evaluated 2 novel immunoassays
targeting MMP-generated neoepitope fragments of 2 of the
most important components of the vascular basement
membrane, C4M of collagen type IV and LG1M of laminin,
as potential prognostic markers of cardiovascular events,
cardiovascular mortality, and all-cause mortality in patients
with known atherosclerosis.
Our main ﬁndings were that C4M and LG1M predicted all-
cause mortality together with diabetes mellitus and eGFR.
Collagen type IV and laminin are the 2 major constituents
of the arterial basement membrane.20,21 These proteins
contribute to the network required to maintain the tissue
integrity of the basement membrane.22,23
Table 2. Clinical Characteristics of the Study Cohort Divided by the Median of LG1M (Cutoff, 8.5 ng/mL)
Low (n=411) High (n=375) P Value
Age 71 (66–77) 72 (66–78) 0.244
Male sex, n (%) 272 (66.2) 230 (61.3) 0.158
Degree of stenosis, % 85 (75–95) 90 (75–95) 0.010*
BMI 26.2 (24–29.2) 26.55 (24.00–29.30) 0.820
Current smoker, n (%) 116 (28.2) 139 (37.1) 0.008*
Hypertension, n (%) 109 (26.5) 78 (20.8) 0.105
Symptomatic plaque, n (%) 307 (74.7) 302 (80.5) 0.050
Fasting plasma levels of lipids
Cholesterol, mmol/L 4.3 (3.6–5.2) 4.4 (3.6–5.3) 0.424
LDL, mmol/L 2.5 (1.9–3.3) 2.6 (1.9–3.5) 0.384
HDL, mmol/L 1.2 (0.94–1.50) 1.1 (0.91–1.40) 0.039*
Triglycerides, mmol/L 1.2 (0.9–1.7) 1.3 (1.0–1.8) 0.345
Diabetes mellitus, n (%) 98 (23.8) 100 (26.7) 0.363
Coronary artery disease, n (%) 150 (36.5) 145 (18.4) 0.735
CRP, mmol/L 2.0 (0.73–4.00) 4.55 (1.93–9.93) <0.001*
HbA1c, mmol/mol 2.84 (38.00–51.04) 43.0 (38.0–53.6) 0.715
Medications, n (%)
Statins 372 (90.5) 331 (88.3) 0.306
Antihypertensive drugs 315 (76.6) 301 (80.3) 0.218
eGFR mL/min per 1.73 m2 65.08 (53.32–80.14) 64.66 (48.09–78.40) 0.248
Nonnormally distributed data variables are presented as median (interquartile range). Categorical values are presented as numbers and percentages. BMI indicates body mass index; CRP,
C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Signiﬁcant difference between low and high levels of LG1M.
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The C4M and LG1M neoepitopes are generated by some of
the most expressed MMPs in human atherosclerosis through
their degradation of collagen type IV and laminin.21,24,25
Plaque rupture is considered to be a potential consequence of
excessive extracellular matrix degradation caused by
increased MMP activity, especially MMP-12 activity.26 Herein,
markers measuring active extracellular matrix remodeling
could potentially be used to monitor plaque remodeling and to
identify patients at increased risk of a cardiovascular event.27
We observed increased serum levels of C4M in patients
who had preoperative cerebrovascular symptoms before
surgery. In line with these ﬁndings, signiﬁcant correlations
between C4M and LG1M and several MMPs were identiﬁed. It
is noteworthy that MMP-12, important in plaque vulnerability
and collagen type IV degradation, correlated to both C4M and
LG1M levels.26 However, the correlations of C4M and LG1M
to MMPs should be interpreted with caution because of the
rather low r values and thereby weak correlations. Neverthe-
less, our ﬁnding in the present study do not provide any
evidence for the role of C4M or LG1M as markers of
basement membrane degradation in the vessel wall. Neither
can we rule out that the increased levels of these components
contribute to the development of symptoms or if they are a
consequence of the event of a plaque rupture. However, no
correlation between C4M levels (1 day before surgery) and
the time between surgery and symptoms/plaque rupture was
found (r=0.001, P=0.9). Taking this into consideration, it is
more likely that C4M levels are associated with the underlying
ongoing pathology, rather than a result from the plaque
rupture.
Table 3. Uni- and -Multivariate Cox Proportional Hazard Regression Model for Cardiovascular Events and Cardiovascular- and All-
Cause Mortality for C4M and LG1M
Variable
Cardiovascular Events Cardiovascular Mortality All-Cause Mortality
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Univariate Cox analysis
C4M* 1.51 (0.99–2.29) 0.056 1.72 (0.86–3.46) 0.128 2.05 (1.16–3.61) 0.013†
Multivariate Cox analysis
C4M* 1.48 (0.95–2.32) 0.083 1.65 (0.77–3.52) 0.164 2.08 (1.12–3.87) 0.020†
Age 0.99 (0.96–1.03) 0.705 1.00 (0.94–1.07) 0.928 1.03 (0.98–1.08) 0.297
Sex 1.39 (0.87–2.22) 0.164 1.61 (0.75–3.43) 0.219 1.26 (0.72–2.21) 0.425
Hypertension 0.81 (0.50–1.29) 0.365 0.91 (0.40–2.08) 0.818 0.97 (0.51–1.85) 0.936
Diabetes mellitus 1.53 (0.97–2.42) 0.069 2.06 (1.01–4.19) 0.046† 1.94 (1.12–3.36) 0.018†
Smoking 0.86 (0.52–1.43) 0.568 0.53 (0.19–1.51) 0.235 1.05 (0.53–2.07) 0.892
Cholesterol 1.04 (0.87–1.24) 0.686 1.21 (0.91–1.62) 0.189 1.02 (0.80–1.29) 0.888
eGFR 0.99 (0.97–1.00) 0.037† 0.96 (0.94–0.99) 0.004† 0.97 (0.96–0.99) 0.004†
Variable HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Univariate Cox analysis
LG1M* 1.33 (0.90–1.96) 0.157 1.91 (1.00–3.64) 0.050 2.01 (1.21–3.34) 0.007†
Multivariate Cox analysis
LG1M* 1.035 (0.89–2.05) 0.163 1.48 (0.74–2.98) 0.269 1.81 (1.05–3.10) 0.031†
Age 0.99 (0.96–1.03) 0.716 1.00 (0.94–1.06) 0.954 1.02 (0.98–1.07) 0.361
Sex 1.35 (0.85–2.15) 0.202 1.50 (0.71–3.18) 0.287 1.17 (0.67–2.04) 0.587
Hypertension 0.81 (0.51–1.30) 0.376 0.89 (0.39–2.05) 0.780 0.96 (0.51–1.83) 0.906
Diabetes mellitus 1.48 (0.93–2.34) 0.097 1.98 (0.97–4.06) 0.061 1.88 (1.08–3.25) 0.025†
Smoking 0.88 (0.53–1.46) 0.611 0.55 (0.20–1.55) 0.260 1.07 (0.55–2.11 0.837
Cholesterol 1.03 (0.86–1.23) 0.779 1.19 (0.90–1.58) 0.221 1.01 (0.80–1.27) 0.948
eGFR 0.99 (0.97–1.00) 0.028† 0.96 (0.94–0.99) 0.004† 0.97 (0.95–0.99) 0.002†
Known cardiovascular risk factors, age, sex, hypertension, diabetes mellitus, current smoking, total cholesterol, and eGFR were included in the model. Data are presented as hazard ratio
(95% CI). CI indicates conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio.
*Above vs below median.
†Statistical signiﬁcant.
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As the basement membrane plays an important role in
maintaining endothelial integrity and function, degradation of
the basement membrane might be one possible cause of
endothelial erosions.7 An alternative explanation would be
that the association between serum levels of basement
membrane neoepitopes and future death, as well as a trend
for cardiovascular events, reﬂects an increased leakage of the
neoepitopes into the circulation and not per se an increased
degradation of the basement membrane. A dysfunctional
endothelium is also associated with a higher risk of future
cardiovascular events.28 A defective endothelium could likely
also be involved in the development of a rupture-prone plaque
with or without an increased degradation of the ﬁbrous cap or
the basement membrane.
Finally, we observed that serum levels of C4M and LG1M
were associated with all-cause mortality, together with
diabetes mellitus and eGFR. This might suggest that neoepi-
topes may not only reﬂect cardiovascular pathology but also
other biological processes that affect the basement mem-
brane such as aging, kidney failure, or diseases with high
tissue turnover, such as cancer.29,30 However, the possible
role of these marker in noncardiovascular processes is
beyond the scope of this study and warrant new, dedicated
investigations.
Figure 3. Levels of (A) C4M and (B) LG1M in patients with an asymptomatic vs symptomatic plaque.
Differences were calculated by a nonparametric Wilcoxon-Mann–Whitney t test. Data are presented as
Tukey boxplots.
Figure 2. Associations of C4M and LG1M with all-cause mortality. Sixty-four patients died during the 6-year follow-up period. A, Kaplan–Meier
curves for all-cause mortality were performed for C4M levels above and below the median. Patients with circulating C4M levels higher than the
median were signiﬁcantly more likely to die (P=0.011). B, Kaplan–Meier curves for all-cause mortality were performed for LG1M levels above and
below the median. Patients with circulating LG1M levels higher than the median were signiﬁcantly more likely to die (P=0.006).
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The strength of this study is the use of a large prospective
cohort of patients with advanced atherosclerosis to explore
the association of 2 novel biomarkers of basement membrane
remodeling with relevant clinical end points during a large
follow-up period. The limitations include the lack of mecha-
nistic explanations for the associations between the biomark-
ers and the clinical outcomes and the fact that the laminin c1
chain and collagen type IV a1 chain are expressed in the
majority of the basement membranes throughout the body.
Therefore, the biomarkers cannot be fully qualiﬁed as vascular
speciﬁc. Despite the size of the cohort, it did not have enough
events to allow a separated analysis between the different
types of cardiovascular events (eg, coronary versus cere-
brovascular). Because we saw that eGFR was a strong
predictor in the regression analysis, we cannot exclude a
contribution from the kidney extracellular matrix to the
fragments of LG1M and C4M measured in serum. Finally, we
can also not extrapolate the ﬁndings to healthy populations or
populations with less advanced atherosclerosis, as this will
demand more studies in different cohorts.
Conclusions
In conclusion, increased levels of the neoepitope marker of
collagen type IV degradation, C4M, and laminin c1 chain,
LG1M, predicted all-cause mortality, together with diabetes
mellitus and eGFR in patients with advanced atherosclerosis.
These novel serum markers of basement membrane remod-
eling might be potential clinical tools to identify, among
patients with known advanced atherosclerosis, those who are
at an increased risk for death, demanding tighter or more
intensive treatment strategies.
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